Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 9/20 | 0.95 |
| ▸ | TAF1 | P21675 | 4/20 | 0.82 |
| ▸ | CECR2 | Q9BXF3 | 5/20 | 0.75 |
| ▸ | BRD9 | Q9H8M2 | 5/20 | 0.60 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.60 |
| ▸ | BRD2 | P25440 | 1/20 | 0.60 |
| ▸ | SMARCA4 | P51532 | 1/20 | 0.60 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.60 |
| ▸ | BRDT | Q58F21 | 1/20 | 0.60 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.60 |
| ▸ | TAF1L | Q8IZX4 | 1/20 | 0.60 |
| ▸ | BRD7 | Q9NPI1 | 1/20 | 0.60 |
| ▸ | BRWD1 | Q9NSI6 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17748899 | 0.98 | BRD4 (1.00) | BRD4TAF1CECR2BRD9TRIM24 | |
| SCHEMBL19869923 | 0.92 | BRD4 (1.00) | BRD4TAF1CECR2BRD9TRIM24 | |
| SCHEMBL19869920 | 0.91 | BRD4 (0.83) | BRD4TAF1CECR2BRD9TRIM24 | |
| SCHEMBL17748864 | 0.91 | BRD4 (0.85) | BRD4TAF1CECR2BRD9TRIM24 | |
| SCHEMBL17748889 | 0.90 | TAF1 (1.00) | BRD4TAF1CECR2BRD9TRIM24 | |
| SCHEMBL17748904 | 0.89 | BRD4 (0.80) | BRD4TAF1CECR2BRD9TRIM24 | |
| SCHEMBL17748915 | 0.86 | BRD4 (0.76) | BRD4TAF1CECR2BRD9TRIM24 | |
| SCHEMBL17748907 | 0.86 | CECR2 (1.00) | BRD4TAF1CECR2BRD9TRIM24 | |
| SCHEMBL17748896 | 0.85 | CECR2 (1.00) | BRD4TAF1CECR2BRD9TRIM24 | |
| SCHEMBL17748942 | 0.85 | BRD4 (1.00) | BRD4TAF1CECR2BRD9TRIM24 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3265453-B1 | NEW PYRIDINONES AND ISOQUINOLINONES AS INHIBITORS OF THE BROMODOMAIN BRD9 | BOEHRINGER INGELHEIM INT (DE) | 2022-06-29 | — | — | EP | disclosed |
| US-11319318-B2 | Pyridinones and isoquinolinones as inhibitors of the bromodomain BRD9 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2022-05-03 | — | — | US | disclosed |
| US-20180044335-A1 | New Pyridinones and Isoquinolinones as Inhibitors of the Bromodomain BRD9 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2018-02-15 | — | — | US | disclosed |
| US-20180044335-A1 | New Pyridinones and Isoquinolinones as Inhibitors of the Bromodomain BRD9 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2018-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180044335-A1 | New Pyridinones and Isoquinolinones as Inhibitors of the Bromodomain BRD9 | BRD9, BRD1, BRD2 | BRD4 5/4885TAF1 742/4885CECR2 821/4885 |
| US-11319318-B2 | Pyridinones and isoquinolinones as inhibitors of the bromodomain BRD9 | BRD9, BRD1, BRD2 | BRD4 6/4885TAF1 901/4885CECR2 1168/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.